Day: March 21, 2024

Globex Acquires Gold Exploration Target in Arizona, USA

Written by Customer Service on March 21, 2024. Posted in Mergers And Acquisitions.

ROUYN-NORANDA, Quebec, March 21, 2024 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to report to shareholders that it has acquired by staking 24 unpatented lode claims totaling a surface area of 200.67 ha (495.84 acres) in Mohave County, northwestern Arizona, USA. The property herein called the Salt Spring project was staked to cover a large number of gold-bearing quartz veins, small historic mine workings and prospects. The project area is at the northernmost margin of the historic Gold Basin Mining District. This district is large, about 18 km (about 11.18 mi) long north-south and 7 to 11 km...

Redis Acquires Speedb to Supercharge End-to-End Application Performance at Lower Cost

Written by Customer Service on March 21, 2024. Posted in Mergers And Acquisitions.

The data storage engine joins the world’s fastest in-memory datastore to strengthen application performance across caching and real-time use cases MOUNTAIN VIEW, Calif., March 21, 2024 (GLOBE NEWSWIRE) — Redis, the leading real-time data platform, today announced the acquisition of Speedb, the world’s fastest data storage engine, to support a broad array of enterprise applications and use cases with diverse performance requirements. Redis will leverage Speedb to enhance real-time data processing and power low-latency user experiences, all while guaranteeing unmatched cost performance for all applications where speed is critical, including generative AI applications. As enterprises continue to prioritize real-time generative AI applications across their business, the acquisition of Speedb enables Redis to expand beyond DRAM...

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Written by Customer Service on March 21, 2024. Posted in Earnings Releases And Operating Results.

Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continues to progress well; top-line data from this study are expected by the end of 2024. Enrollment in COMPANION-003, the Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC) was completed in the first quarter of 2024; top-line data from Stage 1 of this study are expected by mid-year 2024. Initiated planning of a Phase 2 monotherapy study of CTX-471 (CD137 agonist antibody) in patients with advanced melanoma whose tumors express a newly identified biomarker of CTX-471 activity. Additionally, enrollment of patients in the combination arm of CTX-471 with KEYTRUDA® Phase 1b study is ongoing. Advanced CTX-8371 (PD-1 x PD-L1 bispecific antibody) into Phase...

Ascent Solar Technologies Announces Substantial Debt Reduction and Plan for Full Payoff

Written by Customer Service on March 21, 2024. Posted in Public Companies.

THORNTON, Colo., March 21, 2024 (GLOBE NEWSWIRE) — Ascent Solar Technologies, Inc. (“Ascent,” or the “Company”) (Nasdaq: ASTI), a U.S. innovator in the design and manufacturing of featherweight, flexible thin-film photovoltaic (PV) solutions, today provided a corporate update on the Securities Purchase Contract with two institutional investors previously disclosed on December 19, 2022. Currently, one institutional investor’s notes payable and related liabilities have been completely paid out and the remaining investor has been substantially paid off with an approximate remaining notes payable balance of $6,700 and an approximate $200,000 of payables outstanding. It is Ascent’s intention to pay all remaining balances with this institutional investor upon completion of the next equity raise. ABOUT ASCENT SOLAR TECHNOLOGIES, INC. Backed...

C3is Inc. announces the date for the release of the fourth quarter and twelve months 2023 financial and operating results

Written by Customer Service on March 21, 2024. Posted in Public Companies.

ATHENS, Greece, March 21, 2024 (GLOBE NEWSWIRE) — C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing seaborne transportation services, announced today that it will release its fourth quarter and twelve months financial results for the period ended December 31, 2023 before the market opens in New York on March 26th, 2024. On March 26th, 2024, at 11:00 am ET, the company’s management will host a conference call to present the results and the company’s operations and outlook. Slides and audio webcast: There will also be a live and then archived webcast of the conference call, through C3is Inc. website (www.c3is.pro). Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast. Please note that this will be a listen-only mode presentation. ABOUT C3is...

Discovery Lithium to Acquire Private Lithium Explorer Midex Resources

Written by Customer Service on March 21, 2024. Posted in Mergers And Acquisitions.

Company targets acquisition which includes prospective lithium project in another prominent Canadian mining landscape VANCOUVER, British Columbia, March 21, 2024 (GLOBE NEWSWIRE) — Discovery Lithium Inc. (CSE: DCLI) (OTCQB: DCLIF) (FRA: Q3Q0) (WKN: A3EFKA) (the “Company,” or “Discovery Lithium”), a Canadian exploration company focused on advancing domestic energy freedom through regional lithium discovery, is pleased to announce that the Company has signed a letter of intent (“LOI”) to acquire a 100% interest in Midex Resources, a Canadian lithium exploration company. HighlightsLOI to acquire 100% ownership of Midex Resources. Discovery Lithium to acquire 43,000-hectare land position in known li-bearing pegmatite fields with resources within northwestern Ontario. Crescent Lake Project is on-strike with ASX-listed Green Technology...

Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines

Written by Customer Service on March 21, 2024. Posted in Public Companies.

MEDIA RELEASEEUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in Europe Additional manufacturing area of 3,000m2 means Kundl can now manufacture 240 million packages per year Represents capacity increase of 20% over 2023 and more than doubling from 2021 output levels Automation and innovative technologies allow production of one billion more penicillin tablets and doubling of output for key pediatric formulation Latest investment follows commissioning of EUR 150m antibiotic active ingredient facility — on stream since November 2023Basel, March 21, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today opened a new production facility in Kundl, Austria, to serve more patients with affordable life-saving drugs produced entirely...

Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider

Written by Customer Service on March 21, 2024. Posted in Public Companies.

Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics’ commitment to excellence and innovation in the field of employee health testing. ManageHR’s annual list recognizes companies that excel in providing cutting-edge solutions and services for employee health testing. Psychemedics was selected for its exceptional performance, industry leadership, and dedication to delivering reliable and accurate testing services. “We are honored to be recognized as one of the Top 10 Employee Health Testing Services Providers,” said Brian Hullinger, Chief Executive Officer and President of Psychemedics...

SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research

Written by Customer Service on March 21, 2024. Posted in Public Companies.

MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that MitoCareX Bio Ltd. (“MitoCareX”), the Company’s venture with Dr. Alon Silberman that focuses on drug discovery and the development of cancer therapeutics by targeting the mitochondrial SLC25 protein family, had virtually screened millions of small molecules by using its computationally advanced drug discovery platform, which resulted in the identification of several molecules that could be used for potential anti-cancer treatments. As...

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Written by Customer Service on March 21, 2024. Posted in Earnings Releases And Operating Results.

Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC) Based on early evidence of clinical activity with NC410 combo, expanding ovarian and CRC cohorts with data updates in 2024 LNCB74, in collaboration with LegoChem, planned filing of an IND by year-end 2024 Restructuring of our operations, including a reduction in workforce to better align resources toward prioritized programs Cash of approximately $108 million, combined with the restructuring, now expected to fund operations into the second half of 2026BELTSVILLE, Md. – March 21, 2024, March 21, 2024 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer today provided a business update...

Day: March 21, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice